C. Hoeller

发表

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells.

H. Pehamberger, V. Sexl, F. Roka, 2005, The Journal of investigative dermatology.

A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis

M. Malumbres, A. Green, C. Bock, 2013, Cancer cell.

IL28B Polymorphism Cannot Predict Response to Interferon Alpha Treatment in Patients with Melanoma

H. Kittler, H. Pehamberger, P. Ferenci, 2014, PloS one.

Inverse Method to Obtain Blocked Forces of Vibrating Sound Sources in Buildings

C. Hoeller, B. Gibbs, 2017 .

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

H. Pehamberger, K. Wolff, T. Lucas, 2000, The Lancet.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

A. Hauschild, R. Dummer, K. Peris, 2018, European Journal of Cancer.

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee

B. Schilling, S. Puig, V. Sondak, 2020 .

Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma

A. Haug, Michael Weber, M. Mayerhoefer, 2019, Molecular Imaging and Biology.

Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases.

H. Pehamberger, K. Wolff, B. Jansen, 2001, The Journal of investigative dermatology.

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).

D. Schadendorf, P. Ascierto, R. Dummer, 2019, European journal of cancer.

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.

I. Zalaudek, A. Hauschild, J. Malvehy, 2020, European journal of cancer.

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

D. Schadendorf, P. Ascierto, M. Smylie, 2020, Journal for immunotherapy of cancer.

CXCL5 Facilitates Melanoma Cell-Neutrophil Interaction and Lymph Node Metastasis.

E. Wagner, E. Buchberger, P. Petzelbauer, 2018, The Journal of investigative dermatology.

Clusterin regulates drug-resistance in melanoma cells.

H. Pehamberger, M. Gleave, V. Sexl, 2005, The Journal of investigative dermatology.

Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma

P. Ascierto, R. Dummer, J. Wolchok, 2022, Cancers.

Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC).

I. Zalaudek, J. Malvehy, R. Dummer, 2019, European journal of cancer.

ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee.

B. Schilling, S. Puig, V. Sondak, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

S. Haferkamp, R. Dummer, J. Kirkwood, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)

James R. Anderson, J. Kirkwood, A. Ribas, 2021, Annals of Oncology.

ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee.

B. Schilling, S. Puig, V. Sondak, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

B. Schilling, S. Puig, V. Sondak, 2020 .

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy.

R. Dummer, S. Patel, C. Blank, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel immune checkpoints beyond PD-1 in advanced melanoma

C. Hoeller, V. Paulitschke, N. Zila, 2021, memo - Magazine of European Medical Oncology.

Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in Large Arteries.

M. Mitterhauser, G. Karanikas, A. Haug, 2020, Circulation.

LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY

G. Linette, F. Hodi, S. D'Angelo, 2014 .

In vivo imaging of cutaneous T-cell lymphoma migration to the skin.

L. Ng, W. Weninger, A. Rook, 2009, Cancer research.

Talimogene laherparepvec (T‐VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report

A. Stepan, C. Hoeller, K. Uyanik-Ünal, 2019, The British journal of dermatology.

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

A. Ribas, F. Hodi, J. Schachter, 2018, British Journal of Cancer.

Sentinel node status in melanoma patients is not predicitive for overall survival upon multivariate analysis

H. Kittler, H. Pehamberger, K. Wolff, 2005, British Journal of Cancer.

A rare case of primary rhabdoid melanoma of the urinary bladder treated with ipilimumab, an anti-CTLA 4 monoclonal antibody

H. Pehamberger, K. Harmankaya, A. Haitel, 2012, Melanoma research.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

A. Hauschild, D. Schadendorf, P. Ascierto, 2017, European journal of cancer.

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention.

I. Zalaudek, A. Hauschild, J. Malvehy, 2020, European journal of cancer.

MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents.

C. Hoeller, K. Macfelda, R. Kunstfeld, 2004, Magnetic resonance imaging.

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

D. Schadendorf, P. Ascierto, M. Smylie, 2017, The Lancet. Oncology.

Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.

H. Pehamberger, K. Wolff, C. Thallinger, 2005, The Journal of investigative dermatology.

Betulinic Acid-induced Mcl-1 Expression in Human Melanoma — Mode of Action and Functional Significance

H. Pehamberger, C. Thallinger, B. Jansen, 2002, Molecular medicine.

Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.

M. Preusser, S. Zöchbauer-Müller, I. Pabinger, 2020, Blood.

The interplay of CDK4 and CDK6 in melanoma

C. Hoeller, K. Kollmann, S. Blunder, 2019, Oncotarget.

Migratory Dermal Dendritic Cells Act as Rapid Sensors of Protozoan Parasites

L. Ng, P. Scott, W. Weninger, 2008, PLoS pathogens.

Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients

L. Kwong, E. Richtig, M. Pichler, 2017, The British journal of dermatology.

Targeting Signaling Pathways – In the Search of Melanoma’s Achilles’ Heel

M. Herlyn, N. Haass, C. Hoeller, 2008 .

Gaining momentum: New options and opportunities for the treatment of advanced melanoma.

O. Michielin, C. Hoeller, 2015, Cancer treatment reviews.

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

D. Schadendorf, A. Ribas, K. Emancipator, 2018, European journal of cancer.

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives

A. Hauschild, C. Robert, O. Michielin, 2020, British Journal of Cancer.

A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis

M. Malumbres, A. Green, C. Bock, 2016, Cancer cell.

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis

K. Buder-Bakhaya, A. Hauschild, D. Schadendorf, 2022, European Journal of Cancer.

Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe

J. Malvehy, R. Dummer, K. Harrington, 2018, European Journal of Dermatology.

Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study

I. Wolf, S. Pilz, E. Richtig, 2018, PloS one.

Telemedically augmented palliative care

H. Watzke, C. Hoeller, M. Binder, 2019, Wiener klinische Wochenschrift.

Meeting report from the 2011 international melanoma congress, Tampa, Florida

A. Bosserhoff, K. Flaherty, A. Ribas, 2012, Pigment cell & melanoma research.

LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations

D. Schadendorf, P. Ascierto, R. Dummer, 2017 .

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

D. Schadendorf, G. Linette, C. Horak, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

The future of combination therapies in advanced melanoma

C. Hoeller, 2020, memo - Magazine of European Medical Oncology.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

A. Hauschild, R. Dummer, K. Peris, 2018, European journal of cancer.

Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.

Dirk Schadendorf, Axel Hauschild, Reinhard Dummer, 2014, European journal of cancer.

Vemurafenib impairs the repair of ultraviolet radiation-induced DNA damage

S. Kimeswenger, C. Jantschitsch, C. Hoeller, 2019, Melanoma research.

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

A. Hauschild, K. Kähler, H. Moch, 2015, PloS one.

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.

I. Zalaudek, A. Hauschild, R. Dummer, 2017, European journal of cancer.

Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries

R. Karls, A. Lallas, J. Paoli, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

The evolving field of Dermato‐oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force

A. Enk, M. Arenbergerova, A. Lallas, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations

T. Beyer, W. Wadsak, G. Karanikas, 2019, European Journal of Nuclear Medicine and Molecular Imaging.

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).

D. Schadendorf, P. Ascierto, R. Dummer, 2019, European journal of cancer.

Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab.

H. Pehamberger, R. Dummer, J. Wolchok, 2014 .

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

A. Ribas, F. Hodi, J. Schachter, 2018, British Journal of Cancer.

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors

R. Dummer, O. Michielin, C. Hoeller, 2017, Cancer Immunology, Immunotherapy.

Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma

P. Ascierto, C. Blank, Z. Szabo, 2016, Cancer Immunology, Immunotherapy.

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

R. Dummer, R. Scolyer, C. Blank, 2016, Oncoimmunology.

Pretherapeutic laboratory findings, extent of metastasis and choice of treatment as prognostic markers in ocular melanoma– a single centre experience

H. Pehamberger, K. Harmankaya, C. Hoeller, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.

A. Gesierich, P. Ascierto, R. Dummer, 2018 .

Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma

H. Pehamberger, C. Hoeller, V. Paulitschke, 2009, Clinical Cancer Research.

Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody.

H. Pehamberger, J. Wolchok, K. Harmankaya, 2013 .

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

E. Richtig, O. Michielin, C. Hoeller, 2021, Journal for ImmunoTherapy of Cancer.

Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).

R. Scolyer, E. Rozeman, C. Blank, 2017 .

Real life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland

E. Richtig, O. Michielin, C. Hoeller, 2019, Annals of Oncology.

Knowledge and Influence of Predatory Journals in Dermatology: A Pan-Austrian Survey.

A. Steiner, T. Deinlein, W. Hoetzenecker, 2019, Acta dermato-venereologica.

Myofibroblast stroma differentiation in infiltrative basal cell carcinoma is accompanied by regulatory T‐cells

P. Petzelbauer, C. Hoeller, B. Lichtenberger, 2022, Journal of cutaneous pathology.

PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis

D. Schadendorf, C. Horak, P. Ascierto, 2016 .

Erythema nodosum‐like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature

C. Berking, K. Kähler, S. Ugurel, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Abstract CT004: KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma

C. Berking, D. Schadendorf, A. Ribas, 2016 .

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.

A. Lallas, I. Zalaudek, A. Hauschild, 2023, European journal of cancer.

Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).

D. Schadendorf, P. Ascierto, R. Dummer, 2017 .

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.

A. Lallas, I. Zalaudek, A. Hauschild, 2023, European journal of cancer.

Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)—Phase II data covering impact of concomitant haematological malignancies

E. Richtig, V. Nguyen, M. Laimer, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)

P. Ascierto, J. Kirkwood, P. Durani, 2023, SKIN The Journal of Cutaneous Medicine.

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

A. Hauschild, D. Schadendorf, P. Ascierto, 2023, Nature Medicine.

Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).

J. Taube, J. Kirkwood, M. Del Vecchio, 2023, Journal of Clinical Oncology.

P32 Erlotinib in combination with different chemotherapeutics is active in a SCID mouse/human melanoma model

H. Pehamberger, C. Hoeller, N. Schicher, 2010 .